Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain

View ORCID ProfileGabriella O. Estevam, View ORCID ProfileEdmond M. Linossi, View ORCID ProfileChristian B. Macdonald, View ORCID ProfileCarla A. Espinoza, View ORCID ProfileJennifer M. Michaud, View ORCID ProfileWillow Coyote-Maestas, View ORCID ProfileEric A. Collisson, View ORCID ProfileNatalia Jura, View ORCID ProfileJames S. Fraser
doi: https://doi.org/10.1101/2023.08.03.551866
Gabriella O. Estevam
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States
2Tetrad Graduate Program, University of California San Francisco, San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriella O. Estevam
Edmond M. Linossi
3Cardiovascular Research Institute, University of California San Francisco, San Francisco, United States
4Department of Cellular and Molecular Pharmacology, University of California San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edmond M. Linossi
Christian B. Macdonald
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian B. Macdonald
Carla A. Espinoza
2Tetrad Graduate Program, University of California San Francisco, San Francisco, United States
3Cardiovascular Research Institute, University of California San Francisco, San Francisco, United States
4Department of Cellular and Molecular Pharmacology, University of California San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carla A. Espinoza
Jennifer M. Michaud
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer M. Michaud
Willow Coyote-Maestas
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States
7Quantitative Biosciences Institute, University of California, San Francisco, United States, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Willow Coyote-Maestas
Eric A. Collisson
5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, United States
6Department of Medicine/Hematology and Oncology, University of California, San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric A. Collisson
Natalia Jura
3Cardiovascular Research Institute, University of California San Francisco, San Francisco, United States
4Department of Cellular and Molecular Pharmacology, University of California San Francisco, United States
7Quantitative Biosciences Institute, University of California, San Francisco, United States, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Natalia Jura
James S. Fraser
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States
7Quantitative Biosciences Institute, University of California, San Francisco, United States, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James S. Fraser
  • For correspondence: [email protected]
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

MET is a receptor tyrosine kinase (RTK) responsible for initiating signaling pathways involved in development and wound repair. MET activation relies on ligand binding to the extracellular receptor, which prompts dimerization, intracellular phosphorylation, and recruitment of associated signaling proteins. Mutations, which are predominantly observed clinically in the intracellular juxtamembrane and kinase domains, can disrupt typical MET regulatory mechanisms. Understanding how juxtamembrane variants, such as exon 14 skipping (METΔEx14), and rare kinase domain mutations can increase signaling, often leading to cancer, remains a challenge. Here, we perform a parallel deep mutational scan (DMS) of the MET intracellular kinase domain in two fusion protein backgrounds: wild type and METΔEx14. Our comparative approach has revealed a critical hydrophobic interaction between a juxtamembrane segment and the kinase ⍺C-helix, pointing to potential differences in regulatory mechanisms between MET and other RTKs. Additionally, we have uncovered a β5 motif that acts as a structural pivot for the kinase domain in MET and other TAM family of kinases. We also describe a number of previously unknown activating mutations, aiding the effort to annotate driver, passenger, and drug resistance mutations in the MET kinase domain.

Competing Interest Statement

JSF is a consultant for, has equity in, and receives research support from Relay Therapeutics. N.J. is a founder of Rezo Therapeutics and a shareholder of Rezo Therapeutics, Sudo Therapeutics, and Type6 Therapeutics. N.J. is a SAB member of Sudo Therapeutics, Type6 Therapeutic and NIBR Oncology. The Jura laboratory has received sponsored research support from Genentech, Rezo Therapeutics and Type6 Therapeutics. E.A.C. is a consultant at IHP Therapeutics, Valar Labs, Tatara Therapeutics and Pear Diagnostics, reports receiving commercial research grants from Pfizer, and has stock ownership in Tatara Therapeutics, HDT Bio, Clara Health, Aqtual, and Guardant Health.

Footnotes

  • Corrected labels for supplemental figures in the revised mansucript.

  • https://github.com/fraser-lab/MET_KinaseDomain_DMS

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted May 07, 2024.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain
Gabriella O. Estevam, Edmond M. Linossi, Christian B. Macdonald, Carla A. Espinoza, Jennifer M. Michaud, Willow Coyote-Maestas, Eric A. Collisson, Natalia Jura, James S. Fraser
bioRxiv 2023.08.03.551866; doi: https://doi.org/10.1101/2023.08.03.551866
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain
Gabriella O. Estevam, Edmond M. Linossi, Christian B. Macdonald, Carla A. Espinoza, Jennifer M. Michaud, Willow Coyote-Maestas, Eric A. Collisson, Natalia Jura, James S. Fraser
bioRxiv 2023.08.03.551866; doi: https://doi.org/10.1101/2023.08.03.551866

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Molecular Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (6022)
  • Biochemistry (13708)
  • Bioengineering (10436)
  • Bioinformatics (33157)
  • Biophysics (17109)
  • Cancer Biology (14173)
  • Cell Biology (20106)
  • Clinical Trials (138)
  • Developmental Biology (10868)
  • Ecology (16018)
  • Epidemiology (2067)
  • Evolutionary Biology (20346)
  • Genetics (13395)
  • Genomics (18634)
  • Immunology (13750)
  • Microbiology (32164)
  • Molecular Biology (13392)
  • Neuroscience (70069)
  • Paleontology (526)
  • Pathology (2190)
  • Pharmacology and Toxicology (3741)
  • Physiology (5864)
  • Plant Biology (12020)
  • Scientific Communication and Education (1814)
  • Synthetic Biology (3367)
  • Systems Biology (8166)
  • Zoology (1841)